|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Heart failure显示文摘 | John JV McMurray Marc A Pfeffer | 2005 | 2005 (9474)2005，，9474： | 1 |
| 2 | Comparison of vasopeptidase inhibitor,omapatrilat,and lisinopril on exercise tolerance and morbidity in patients with heart failure:IMPRESS randomised trial显示文摘 | Rouleau Jean L Pfeffer Marc A Stewart Duncan J | 2000 | Lancet2000，356，： | 1 |
| 3 | Valsartan,Captopril,or Both in Myocardial Infarction Complicated by Heart Failure,Left Ventricular Dysfunction,or Both显示文摘 | Marc A Pfeffer MD Ph D | 2003 | The New England Journal of Medicine2003，349，： | 1 |
| 4 | Heart failure显示文摘 | John JV McMurray Marc A Pfeffer | 2005 | The Lancet2005，，9474： | 1 |
| 5 | Valsartan, capto- pril,or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both显示文摘 | Marc A Pfeffer john JV Mcmurray eric J | 2003 | Engl J Med2003，349，20： | 1 |
| 6 | Exercise Training as Therapy for Heart Failure: Current Status and Future Directions显示文摘 | Jerome L. Fleg Lawton S. Cooper Barry A. Borlaug Mark J. Haykowsky William E. Kraus Benjamin D. Levine Marc A. Pfeffer Ileana L. Pi?a David C. Poole Gordon R. Reeves David J. Whellan Dalane W. Kitzman | 2015 | Circulation: Heart Failure2015，，： | 1 |
| 7 | Irbesartan, captopril,or both in myocardial infarction complicated by heart failure, left ven tricular dysfunction, or both显示文摘 | Marc A Pfeffer MD PhD | 2003 | The New England Journal of Medicine2003，349，22： | 1 |
| 8 | Assessment Of Myocardial Viability And Left Ventricular Function In Patients Supported By A Left Ventricular Assist Device显示文摘 | Deepak K. Gupta Hicham Skali Jose Rivero Patricia Campbell Leslie Griffin Colleen Smith Courtney Foster Brian Claggett Robert J. Glynn Gregory Couper Michael M. Givertz Mandeep R. Mehra Marcelo Di Carli Scott D. Solomon Marc A Pfeffer | 2014 | Journal of Heart and Lung Transplantation2014，，： | 1 |
| 9 | Spironolactone for Heart Fail- ure with Preserved Ejection Fraction显示文摘 | Bertram P Marc A Pfeffer Susan FA | 2014 | N Engl Med2014，370，15： | 1 |
| 10 | Myocardial infarct size and ventricular function in rats显示文摘 | Marc A Pfeffer Janice M | 1979 | Circ Res1979，44，： | 1 |
| 11 | Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme显示文摘 | Marc A Pfeffer Karl Swedberg Christopher B Granger Peter Held John JV McMurray Eric L Michelson Bertil Olofsson Jan ?stergren Salim Yusuf | 2003 | The Lancet2003，，9386： | 1 |
| 12 | Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial显示文摘 | Jean-Claude Tardif John JV McMurray Eric Klug Robert Small Jennifer Schumi Jasmine Choi Jim Cooper Robert Scott Eldrin F Lewis Philippe L L’Allier Marc A Pfeffer | 2008 | The Lancet2008，，9626： | 1 |
| 13 | Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction(results of the CHARM low-left ventricular ejection fraction trials显示文摘 | James B Young MD Mark E Dunlap MD Marc A Pfeffer MD PhD | 2004 | Circulation2004，110，： | 1 |
| 14 | Valsartan,captopril, or both in myocardial infarction comphcated by heart failure, left ventricular dysfunction, or both显示文摘 | Marc A Pfeffer MD John JV | 2003 | N Engl J Med2003，349，： | 1 |
| 15 | Controversies in ventricular remodelling显示文摘 | Lionel H Opie Patrick J Commerford Bernard J Gersh Marc A Pfeffer | 2006 | The Lancet . 2006 (9507)2006，，： | 1 |
| 16 | Isolated systolic hypertension prognostic information provided by pulse pressure显示文摘 | Barry R Davis Marc A Pfeffer | 1999 | Hypertension1999，34，3： | 1 |
| 17 | Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio,not age显示文摘Recent guidelines restricted aspirin(ASA)in primary prevention of cardiovascular disease(CVD)to patients<70 years old and more recent guidance to<60.In the most comprehensive prior meta-analysis,the Antithrombotic Trialists Collaboration reported a significant 12%reduction in CVD with similar benefit−risk ratios at older ages.Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines,four trials were added to an updated meta-analysis.ASA produced a statistically significant 13%reduction in CVD with 95%confidence limits(0.83 to 0.92)with similar benefits at older ages in each of the trials.Primary care providers should make individual decisions whether to prescribe ASA based on benefit−risk ratio,not simply age.When the absolute risk of CVD is>10%,benefits of ASA will generally outweigh risks of significant bleeding.ASA should be considered only after implementation of therapeutic lifestyle changes and other drugs of proven benefit such as statins,which are,at the very least,additive to ASA.Our perspective is that individual clinical judgements by primary care providers about prescription of ASA in primary prevention of CVD should be based on our evidence-based solution of weighing all the absolute benefits and risks rather than age.This strategy would do far more good for far more patients as well as far more good than harm in both developed and developing countries.This new and novel strategy for primary care providers to consider in prescribing ASA in primary prevention of CVD is the same as the general approach suggested by Professor Geoffrey Rose decades ago. | Kyungmann Kim Charles H Hennekens Lisa Martinez J Michael Gaziano Marc A Pfeffer Bianca Biglione Alexander Gitin Jeanne Bell McCabe Thomas D Cook David L DeMets Sarah K Wood | 2021 | Family Medicine and Community Health2021，9，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员